Orange Photonics Unveils LightLab 3 Psychedelics Analyzer, Revolutionizing Analytical Testing for Psychedelic Mushrooms and Infused Products

NEW LONDON, NH – Orange Photonics, a pioneer in analytical testing solutions, is pleased to introduce LightLab 3 Psychedelics (Psy) Analyzer, which allows non-technical users to measure psilocybin, psilocin, and ACO-DMT in psychedelic mushrooms and infused products. This innovative technology, initially developed for cannabis testing applications, is set to play a pivotal role in cultivation, production and regulatory applications.

LightLab 3 Psy Analyzer is an essential on-site testing tool for licensed operators and research institutions. LightLab facilitates data-driven decisions, supporting strain selection, harvest optimization, extraction, accurate dosing, and consumer safety.

According to MJBiz Science, the development of portable testing devices for psilocybin and psilocin analysis is crucial for ensuring accurate dosing and product safety. In a recent newsletter, the company noted that the advanced technology behind LightLab 3 is “paving the way for enhanced quality control and compliance in the emerging field of psychedelics.”

“The rapidly emerging psychedelics market has the opportunity to incorporate on-site potency analysis into every element of manufacturing and regulation.” says Stephanie McArdle, President of Orange Photonics. “Psychedelics product producers are in a position to ensure consumer safety is a primary focus. LightLab 3 Psy Analyzer is optimized for that critical role.”

LightLab 3 Psy Analyzer quantifies the amount of psilocybin, psilocin, and ACO-DMT in psychedelic mushrooms, extracts and infused products, using the same technology favored by nearly all testing laboratories, High Performance Liquid Chromatography (HPLC). LightLab 3’s easy-to-use, portable design empowers non-technical users to generate laboratory-quality data in the field.

Since 2015, LightLab 3 technology has been used by cannabis operators, State and Federal regulators such as the FDA, enforcement, universities and research institutions.

< | >